Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tamoxifen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 8/20 | 0.97 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.97 |
| ▸ | MAPT | P10636 | 3/20 | 0.97 |
| ▸ | MEN1 | O00255 | 3/20 | 0.97 |
| ▸ | TP53 | P04637 | 3/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.97 |
| ▸ | ESRRG | P62508 | 3/20 | 0.97 |
| ▸ | PGR | P06401 | 2/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.97 |
| ▸ | HTR6 | P50406 | 2/20 | 0.97 |
| ▸ | NPC1 | O15118 | 1/20 | 0.97 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.97 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.97 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.97 |
| ▸ | EGFR | P00533 | 1/20 | 0.97 |
| ▸ | GBA1 | P04062 | 1/20 | 0.97 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.97 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tamoxifen SCHEMBL3794383 | 1.00 | ESR1 (0.97) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL119181 | 0.99 | ESR1 (1.00) | ESR1ESR2MAPTMEN1TP53 | |
| SCHEMBL29659348 | 0.99 | ESR1 (1.00) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL17262082 | 0.99 | ESR1 (1.00) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL1056785 | 0.99 | ESR1 (1.00) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL4084 | 0.99 | ESR1 (1.00) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL4085 | 0.99 | ESR1 (1.00) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL17262111 | 0.99 | ESR1 (1.00) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL3046696 | 0.97 | ESR1 (0.97) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL4323848 | 0.97 | ESR1 (0.97) | ESR1ESR2MAPTMEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109153656-B | Crystal form E of tadalafil tamibamide salt and preparation method and application thereof | 苏州晶云药物科技股份有限公司 | 2021-06-25 | — | — | CN | claimed |
| EP-0127128-B1 | PROCESS FOR THE CONVERSION OF THE E ISOMER OF 1,2-DIPHENYL-1-(4-(2-DIMETHYLAMINOETHOXY)-PHENYL)-1-BUTENE TO TAMOXIFEN HCL | Bristol-Myers Company (US) | 1987-02-25 | — | — | EP | claimed |
| EP-0127128-A1 | Process for the conversion of the E isomer of 1,2-diphenyl-1-(4-(2-dimethylaminoethoxy)-phenyl)-1-butene to tamoxifen HCl | Bristol-Myers Company (US) | 1984-12-05 | — | — | EP | claimed |
| CN-116940351-A | Prodrug compositions and methods of treatment | 阿奎斯蒂弗医疗股份有限公司 | 2023-10-24 | — | — | CN | disclosed |
| US-20220241189-A1 | MODIFIED RELEASE DRUG POWDER COMPOSITION COMPRISING GASTRO-RETENTIVE RAFT FORMING SYSTEMS HAVING TRIGGER PULSE DRUG RELEASE | PROVIDENT BANK | 2022-08-04 | — | — | US | disclosed |
| US-11337919-B2 | Modified release drug powder composition comprising gastro-retentive RAFT forming systems having trigger pulse drug release | TRIS PHARMA, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-20210015744-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A FLOATING INTERPENETRATING POLYMER NETWORK FORMING SYSTEM | PROVIDENT BANK | 2021-01-21 | — | — | US | disclosed |
| US-20210015745-A1 | MODIFIED RELEASE DRUG POWDER COMPOSITION COMPRISING GASTRO-RETENTIVE RAFT FORMING SYSTEMS HAVING TRIGGER PULSE DRUG RELEASE | PROVIDENT BANK | 2021-01-21 | — | — | US | disclosed |
| EP-3740189-A1 | MODIFIED RELEASE DRUG POWDER COMPOSITION COMPRISING GASTRO-RETENTIVE RAFT FORMING SYSTEMS HAVING TRIGGER PULSE DRUG RELEASE | Tris Pharma, Inc. (US) | 2020-11-25 | — | — | EP | disclosed |
| EP-3740188-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A FLOATING INTERPENETRATING POLYMER NETWORK FORMING SYSTEM | Tris Pharma, Inc. (US) | 2020-11-25 | — | — | EP | disclosed |
| EP-2815236-A1 | MEANS AND METHODS FOR ASSESSING AN ENDOCRINE DISEASE OR DISORDER | BASF SE (DE) | 2014-12-24 | — | — | EP | disclosed |
| WO-2013121380-A1 | MEANS AND METHODS FOR ASSESSING AN ENDOCRINE DISEASE OR DISORDER | BASF SE (DE) | 2013-08-22 | — | — | WO | disclosed |
| CN-102281903-A | Method and formulation for reducing aggregation of a macromolecule under physiological conditions | — | 2011-12-14 | — | — | CN | disclosed |
| WO-2009142968-A2 | VALPROIC ACID SALTS | OLEMA PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| WO-2006001035-A2 | SYNERGISTIC LIPOSOMAL TAMOXIFEN COMPOSITION FOR TOPICAL APPLICATION AND METHOD OF PREPARING THEREOF. | LIFECARE INNOVATIONS PVT. LTD. (IN) | 2006-01-05 | — | — | WO | disclosed |
| EP-0126470-B1 | PROCESS FOR THE PREPARATION OF TAMOXIFEN | Bristol-Myers Company (US) | 1989-04-12 | — | — | EP | disclosed |
| EP-0127128-B1 | PROCESS FOR THE CONVERSION OF THE E ISOMER OF 1,2-DIPHENYL-1-(4-(2-DIMETHYLAMINOETHOXY)-PHENYL)-1-BUTENE TO TAMOXIFEN HCL | Bristol-Myers Company (US) | 1987-02-25 | — | — | EP | disclosed |
| EP-0127128-A1 | Process for the conversion of the E isomer of 1,2-diphenyl-1-(4-(2-dimethylaminoethoxy)-phenyl)-1-butene to tamoxifen HCl | Bristol-Myers Company (US) | 1984-12-05 | — | — | EP | disclosed |
| EP-0127128-A1 | Process for the conversion of the E isomer of 1,2-diphenyl-1-(4-(2-dimethylaminoethoxy)-phenyl)-1-butene to tamoxifen HCl | Bristol-Myers Company (US) | 1984-12-05 | — | — | EP | disclosed |
| EP-0126470-A1 | Process for the preparation of tamoxifen | Bristol-Myers Company (US) | 1984-11-28 | — | — | EP | disclosed |